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The objective of this special issue is to address recent
research trends and developments about the advancements
of image processing and vision in healthcare. A substantial
number of papers were submitted, and after a thorough peer
review process, some of these were selected to be included
in this special issue. Growth abnormalities (either growth
restriction or large for gestational age) during perinatal and
postnatal life are a hot topic issue, since they are often linked
to alteration of uterine environment caused by placental
insufficiency, maternal metabolic syndrome, and in general
under- or overnutrition of the fetus.These fetal abnormalities
account for the leading causes of perinatal morbidity and
mortality. Moreover, under the hypothesis of developmental
origin of adult diseases, they bear consequences in later
life, programming the infant physiology for a higher risk
of noncommunicable diseases, cardiovascular adult diseases,
and neurodevelopment delay. Low birthweight, caused either
by preterm birth and/or by intrauterine growth restriction,
is recently known to be associated with increased rates of
cardiovascular disease and noninsulin dependent diabetes
in adult life. The “developmental origins of adult disease”
hypothesis, often called “the Barker hypothesis,” proposes
that these diseases originate through adaptations of the fetus
when it is undernourished.These adaptations may be cardio-
vascular, metabolic, or endocrine and they may permanently
change the structure and function of the body, increasing
coronary heart disease risk factors, such as hypertension, type
2 diabetes mellitus, insulin resistance, and hyperlipidaemia.
This hypothesis originally involved from observation by
Barker and colleagues that the regions in England with the
highest rates of infant mortality in the early 20th century
also had the highest rates of mortality from coronary heart
disease decades later. As themost commonly registered cause
of infant death at the start of 20th century was low birth
weight, these observations led to the hypothesis that low birth
weight babies who survived infancy and childhood might be
at increased risk of coronary heart disease in later life. There
is an increased evidence of the link between intrauterine and
perinatal alterations and adult diseases. Although the main
focus so far has been the timing of delivery and follow-up,
the study of the pathophysiology and of possible recovery is of
paramount importance and needs the contributions of physi-
cians from several fields, biologists, bioinformaticians, and
engineers.
The paper by C. Caissutti and V. Berghella presents
a comprehensive review about the most important and
employed guidelines about screening and management of
gestational diabetes (GDM) that affects up to 7% of pregnant
women and is associated with several maternal and perinatal
morbidities. It is well known that GDM represents over
time a risk factor of type 2 diabetes, for both the mother
and the fetus. Nowadays, there are many unsolved questions
concerning the indications of screening, the timing and type
of screening, the criteria for diagnosis, and the population
to screen. The correct identification of universally approved
and shared recommendations should improve the GDM
pregnancy outcomes (gestational hypertension, prematurity,
cesarean deliveries, number of large for gestational age and
small for gestational age fetuses, and 1-minute Apgar scores
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< 7), improving the health care and maintaining a cost-
effective benefit.
The paper by B. Chiofalo et al. takes into account
the role of microRNAs (miRNAs) of the placenta in the
intrauterine growth restriction (IUGR) disease. IUGR could
be considered as a placentation disorder, derived from a dys-
regulation in trophoblast invasion with characteristic tissue
morphology that leads to uteroplacental insufficiency. More
than 1880 miRNAs have been reported in humans and most
of them are expressed in placenta. They seem to modulate
cell development, differentiation, and proliferation, cell type-
specific function, and epigenetic processes. In several cases,
miRNA is significantly different between physiology and
pathological conditions. An abnormal upregulated placental
expression regulating some angiogenic regulatory pathways
seems to increase vascular resistances, also in growth-
restricted human pregnancies. Despite the fact that several
authors have demonstrated a relatively easy and feasible
detection of some miRNAs in maternal whole peripheral
blood, costs of these tests should be reduced in order to
increase cohorts and have stronger evidence. A large cohort
and an adequate statistical power could identify a panel of
biomarkers on maternal peripheral blood for early diagnosis
of IUGR.
The paper of W. M. Curtin et al. analyzes the corre-
lation between Doppler abnormalities in fetuses with sus-
pected IUGR delivered at 37 weeks’ gestation and placental
histopathological lesions, in order to remove the confounding
factor that gestational age has on interpretation of placental
disease.The correct definition of IUGR nowadays is object of
discussion. Up to 70% of fetuses with suspected IUGRmay be
constitutionally small normal infants and the remainder will
be classified as IUGR presumably secondary to a pathologic
placental process. In IUGR at later gestational ages, abnormal
umbilical artery Doppler patterns are less frequent; the
placental pathology is subtler and the lesions can overlapwith
normal pregnancies. This aspect could distinguish the “true”
or “pathologic” IUGR fetuses. In their study the authors
show an association between abnormal Doppler patterns and
the presence of placental pathology in singleton pregnancies
delivered at 37 weeks’ gestation for suspected IUGR. In
particular, an abnormal MCA Doppler had the strongest
association and underscores the limitation of umbilical artery
Doppler alone in IUGR at later gestational ages. Further
investigation and tools for separating the constitutionally
small normal fetus from the IUGR fetus are needed.
The paper of M. G. Clemente et al. describes an obser-
vational retrospective study about the postnatal growth in
a cohort of IUGR infants. The fetal programming theory
postulates that the condition of IUGR is associated with an
increased risk of cardiovascular events in adult life, as stroke,
type II diabetes, metabolic syndrome, and neurocognitive
impairment. At birth, significant differences were found
between IUGR and controls neonates with regard to all
the auxological parameters (weight, head circumference, and
length). During the 1st year, 8 of 12 (70%) IUGR infants
exhibited a significant catch-up growth in the 3 anthropo-
metric parameters and a regular growth until the 3rd year
of follow-up. The majority but not all infants born with
IUGR in our series showed significant postnatal catch-up
growth essentially during the first 12 months of life. The
modern research describes a new personalized medicine
approach through theNewborn IndividualizedDevelopmen-
tal Care and Assessment Program (NIDCAP), conducted
on preterm infants born with severe IUGR by a multidisci-
plinary research working group. It seems to be effective in
ameliorating the neurobehavior, electrophysiology, and brain
structure outcomes. An improved knowledge of the causes of
IUGR will help to develop measures for its prevention and
individualized treatment.
The paper of Q. Guo et al. takes into account the con-
genital heart defect (CHD), one of the most common birth
defects in theworld. Around theworld, periconceptional folic
acid intake in females is thought to reduce the risk of CHD
in the newborn. The methylenetetrahydrofolate reductase
(MTHFR) andmethionine synthase reductase (MTRR) genes
are two of the most important candidate genes for fetal
CHD. However, the correlations between the two genes and
fetal CHD were inconsistent in various reports. This study
is aimed to evaluate the parental effects of the two genes
on fetal CHD via three genetic polymorphisms, MTHFR
677C>T (rs1801133), MTHFR 1298 A>C (rs1801131), and
MTRR 66A>G (rs1801394). Parents with pregnancy history
of fetal CHD were divided into two subgroups in base on
ventricular septal defect (VSD) and non-VSD groups. In
either maternal or paternal group, the MTHFR 677C>T
polymorphism was independently related to fetal non-VSD,
while the MTRR 66A>G polymorphism was independently
related to fetal VSD. The findings of this study could help to
explainwhy the relationship between the two polymorphisms
(MTHFR 677C>T and MTRR 66A>G) and CHD varied
among different studies due to different proportion of VSD
and non-VSD subjects included in those different population
studies.
The paper of D. Darmochwal-Kolarz et al. investi-
gates the role of Interleukin-17 (IL-17), Interleukin-23 (IL-
23), and transforming growth factor 𝛽 (TGF 𝛽) in preg-
nancy complicated by placental insufficiency, fetal growth
restriction, and preeclampsia. In recent years, in order to
clarify the immunological mechanisms responsible for the
proper implantation process, the interest has moved on the
Th1/Th2/Th17 paradigm. Interleukin-17 (IL-17) is a cytokine
with potent proinflammatory properties and has a proven
role in the development of inflammatory processes. More-
over, Interleukin-23, which is produced, among others, by
macrophages and dendritic cells, is an important component
of the inflammatory response. Finally, transforming growth
factor 𝛽 (TGF 𝛽) released, among others, by macrophages,
neutrophils, platelets, and lymphocytes, acts primarily to
reduce the release of proinflammatory cytokines. In addition,
TGF 𝛽 is involved in the processes of angiogenesis, wound
healing, and repair processes, aswell as regulation of the entry
of cells onto the apoptotic pathway. In the group of patients
with placental insufficiency, the maternal sera levels of IL-
17 positively correlated with maternal systolic blood pressure
and the concentrations of TGF 𝛽 were significantly lower,
while IL-23 was comparable with respect to control group. It
seems possible that the increased concentrations of IL-17 and
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the deficiency of TGF 𝛽 in pregnancy complicated by fetal
growth restriction and preeclampsia can be responsible for
the activation of inflammatory response.
The paper of L. Baken et al. discusses the introduction
of three-dimensional (3D) ultrasound in the evaluation of
the crown-rump length (CRL), in particular whether the
embryonic volume (EV), measured by a Virtual Reality (VR)
system, is a better parameter to determine growth restriction
in fetuseswith structural congenital abnormalities, diagnosed
in the first trimester of pregnancy. It is know that the relative
increment of the EV is much larger than the increment of the
CRL during the same period. Moreover, if a too small CRL
is a clinical predictor for miscarriage, chromosomal abnor-
malities (especially trisomy 18), and fetal growth restriction in
the second and third trimester of pregnancy, several authors
underlined that EV was not only smaller in trisomy 18
pregnancies but also in trisomy 21 and trisomy 13 pregnancies.
In this study, measured CRL and EV were converted to
𝑧-scores and to percentages of the expected mean, using
published reference curves of euploid fetuses. The EV was
smaller than expected for gestational age in fetuses with
structural congenital abnormalities, whereas CRL was not.
By measuring EV, first-trimester growth restriction becomes
more evident and might enable an earlier detection of cases
at risk for a congenital abnormality.
The paper of F. Bardanzellu et al. presents a comprehen-
sive reviewof paracetamol efficacy inDuctusArteriosus (DA)
closure in preterm infants, in which the failure or delay of its
spontaneous closure results in the condition of Patent Ductus
Arteriosus (PDA). A prolonged situation of PDA can be
associated with several short- and long-term complications.
Despite years of researches and clinical experience on PDA
management, unresolved questions about the treatment and
heterogeneity of clinical practices still remain, in particular
regarding timing and modality of intervention. Nowadays,
the most reasonable strategy seems to be reserving the
treatment only to hemodynamically significant PDA. The
first-line therapy is medical, and ibuprofen, related to several
side effects especially in terms of nephrotoxicity, is the drug
of choice. Administration of oral or intravenous paraceta-
mol (acetaminophen) recently gained attention, appearing
effective as traditional nonsteroidal anti-inflammatory drugs
(NSAIDs) in PDA closure, with lower toxicity. The results
of the studies analyzed in this review mostly support parac-
etamol efficacy in ductal closure, with inconstant low and
transient elevation of liver enzymes as reported side effect.
More studies are needed to confirm if this therapy shows a
real safety profile and to evaluate its long-term outcomes.
The paper of R. Pintus et al. discusses the most recent lit-
erature about themetabolomic technology and its application
in the cardiologic field, in order to understand the metabolic
shifts that occur even before the manifestation of heart
diseases and to find possible early predictive biomarkers.
Cardiac pathologies are a critical health issue affecting mil-
lions of people worldwide, with a constant mortality rate in
particular in the elderly, a difficult prognosis, and aworsening
in quality of life of affected people. The pathophysiology of
heart pathologies is complex. Recent findings pointed out a
possible pivotal role of mitochondrial dysfunction and the
subsequent altered energy metabolism in cardiac diseases, in
particular in case of heart failure. Moreover, every adverse
event that may occur during pregnancy “shapes” the health
status of the fetus and its development and could affect its
life course, also with cardiovascular problems. Congenital
malformations, gut colonization by microbiota, individual
genetic arrangement, and its interplay with both behavioral
and risk factors, such as drugs assumption, can influence
the occurrence of heart diseases. During the last decade,
animal and human studies have applied metabolomics to
cardiovascular research, using both targeted and untargeted
approaches; as such, metabolic fingerprints have been identi-
fied for several cardiovascular risk factors and diseases.These
techniques could be applied to heart tissue and biofluids,
such as blood, saliva, and urine, with a minimum compliance
needed from the patient, since their collection is not invasive.
Metabolomics, for its peculiarities, seems to be so promising
that several industries are trying to set up kits to immediately
assess the metabolites variations in order to provide a faster
diagnosis and the best treatment specific for that patient,
offering a further step toward the path of the development
of a tailored medicine.
The paper of N. Abdalla et al. describes complete up-
to-date findings from the literature regarding the impact
of chemotherapy on fetal growth. Cancer and pregnancy
rarely coincide. Gynecological cancers are among the most
common malignancies to occur during pregnancy, and
chemotherapy with or without surgery is the primary treat-
ment option.Themain concern of administering chemother-
apy during pregnancy is congenitalmalformation, although it
can be avoided by delaying treatment until after organogene-
sis. The dose, frequency, choice of chemotherapeutic agents,
time of treatment commencement, and method of adminis-
tration can be adjusted to obtain the best maternal treatment
outcomes while simultaneouslyminimizing fetal toxicity. Use
of chemotherapy after the first trimester, while seemingly
safe, can cause fetal growth restriction. However, the exact
effect of chemotherapy on such fetal growth restriction has
not been fully established; information is scarce owing to the
rarity of malignancy occurring during pregnancy, the lack
of uniform treatment protocols, different terminologies for
defining certain fetal growth abnormalities, the influence of
mothers’ preferred options, and ethical issues. Fetal growth
abnormalities are recognized sequelae of chemotherapy, and
the possibility of fetal growth abnormalities as well as the
other side effects of different chemotherapeutic agents should
be discussed with the patients.
The type of malignancy and its stage, the use of surgery
and/or radiotherapy, the stage of pregnancy, the probability
of side effects during treatment, and the patient’s own wishes
influence the final decision regarding treatment. Moreover,
ethical concerns cannot be ignored. Each patient should
ultimately be managed individually with the guidance of a
multidisciplinary team.
The paper of S. A. Ernst et al. investigates what care-
related and maternal risk factors could influence the ante-
natal nondetection of IUGR during pregnancy and exam-
ine if there are specific groups with a higher chance of
nondetected suboptimal fetal growth. Approximately 3% to
4 BioMed Research International
8% of all infants born in developed countries have been
identified as growth restricted. IUGR is a prenatal condition
associated with a higher risk for perinatal morbidity and
mortality, increasing the stillbirth rate fourfold compared
to pregnancies with normally grown fetuses; antenatal non-
detection further increases the rate by a factor of 2. An
early antenatal detection, choosing the optimal time and
method of delivery, and treatment where appropriate could
minimize the risks significantly. However, low antenatal
detection rates of suboptimal fetal growth through routine
fetal ultrasonography have been reported. In fact IUGR has
been reported to be antenatally detected only in one-third
(25% to 32%) of pregnancies with suboptimal fetal growth.
Moreover, the authors identified three factors that influenced
IUGR detection: a higher severity of the growth restriction,
maternal complications/diseases during pregnancy, and a
Doppler examination. The authors did not find statistically
significant differences regarding parental socioeconomic sta-
tus and maternal migration background. Future in-depth
studies with larger study populations should further examine
factors that could increase antenatal detection rates for IUGR.
The paper of S. Norda et al. discusses the role of neonatal
ApoE e4 haplotype on IUGRand its contribution on impaired
fetal growth and the possible link of IUGR with cardiovas-
cular and metabolic diseases later in life. Apolipoprotein E
(ApoE) is an important circulating serum protein involved in
transporting lipids and cholesterol and regulating lipid levels.
Its regulatory functions have been attributed to many bio-
physiological processes including neuronal growth andmod-
ulation of oxidant and inflammatory processes. Cord blood of
IUGRneonates displays lipid changes towards atherosclerotic
profiles. IUGR born babies were found to have lower con-
centrations of high-density lipoprotein cholesterol (HDL-C),
known for having an anti-inflammatory effect and protective
properties against the development of atherosclerosis, while
triglycerides and oxidized low-density lipoprotein (oxLDL)
levels were elevated in samples of umbilical blood compared
to adequate weight newborns. This disrupted cholesterol and
triglyceride handling plays a role in causing suboptimal fetal
development and exposes the newborn to an atherosclerotic
environment early, consequentially giving raise to irreversible
damage to vessels. The association of ApoE e4 with the
development of dyslipidemia and cardiovascular disease is
known. In newborns, carrying the ApoE e2 allele has been
associated with lower fetal cord blood LDL-C levels and
higher levels of HDL-C suggesting a beneficial effect of
this genotype on blood lipid configuration, modulating the
fetal growth and the severity of IUGR. In this cohort, 4885
preterm infants were analyzed. Neonates were categorized
into subgroups of <3rd, 3rd–10th, and >10th birth weight
percentile. The identification of the ApoE genotype was
carried out. No association was found between genotype
and birth weight percentiles in each of the subgroups. ApoE
genotype and low birth weight depict two distinct risk factors
for cardiovascular disease without being directly associated.
The paper of M. Gatta et al. describes that prematurity
has a critical influence on interactive, communicative, and
expressive child behaviour, particularly during the first years
of life. Few studies have stressed the assessment of mother-
father-child interaction in families with preterm children,
generating contradictory results. The authors recruited 78
families, 39 families with preterm children, and 39 families
with full-term children. Results show that families with
preterm children display a low quality of mother-father-child
interactions. After six months, family interactions result is
generally stable, except for some Lausanne Trilogue Play-
scales, reflecting a hard adjustment of parenting style to the
evolution of the child. The Lausanne Trilogue Play is a semi-
standardized observation situation designed to assess the
quality of family interactions. The administration involved
the mother-father-child triad invited to cooperate and work
together in order to conduct an activity. In families with
preterm children, the parenting stress seemed to be correlated
with the quality of mother-father-child interactions.
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